Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$2.49 +5.5%	$4.04	$7.96 ▼ $24.15	$12.56M	0.63	16,805 shs	72,501 shs
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
CLDI Calidi Biotherapeutics	$0.23 -11.7%	$0.40	$0.22 ▼ $3.89	$7.30M	1.07	997,018 shs	1.38 million shs
NKGN NKGen Biotech	$0.22 -9.2%	$0.24	$0.10 ▼ $1.37	$9.80M	1.2	1.57 million shs	122,664 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	-1.67%	-11.61%	-15.41%	-73.24%	-86.84%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	-51.00%	-92.41%
CLDI Calidi Biotherapeutics	-8.74%	-16.10%	-36.62%	-61.25%	+26,009,900.00%
NKGN NKGen Biotech	+7.87%	-16.52%	-17.18%	+50.00%	-79.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	1.9167 of 5 stars	3.8	0.0	0.0	0.0	3.2	0.0	0.0
CLDI Calidi Biotherapeutics	1.7172 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.6
NKGN NKGen Biotech	0.8782 of 5 stars	0.0	5.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
CLDI Calidi Biotherapeutics	3.00	Buy	$10.00	4,255.40% Upside
NKGN NKGen Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest APTO, ALVR, NKGN, and CLDI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/28/2025	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.00 ➝ $6.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
CLDI Calidi Biotherapeutics	$50K	145.99	N/A	N/A	($2.32) per share	-0.10
NKGN NKGen Biotech	$80K	122.48	N/A	N/A	($2.68) per share	-0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	8/7/2025 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
APTO Aptose Biosciences	N/A	1.05	1.05
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
NKGN NKGen Biotech	N/A	0.02	0.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
APTO Aptose Biosciences	26.62%
CLDI Calidi Biotherapeutics	12.53%
NKGN NKGen Biotech	76.17%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
APTO Aptose Biosciences	1.33%
CLDI Calidi Biotherapeutics	6.70%
NKGN NKGen Biotech	10.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
CLDI Calidi Biotherapeutics	38	31.79 million	20.04 million	N/A
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable

APTO, ALVR, NKGN, and CLDI Headlines

Recent News About These Companies

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida

June 23 at 8:05 AM | globenewswire.com

Nkgen biotech sees $2.5 million stock purchase by major shareholder

June 4, 2025 | investing.com

NKGen Biotech Enters Stock Purchase Agreement

May 20, 2025 | tipranks.com

NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer’s readout

May 8, 2025 | fiercebiotech.comF

NKGen Biotech Chairman & CEO Paul Y. Song, M.D.

May 8, 2025 | globenewswire.com

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

May 7, 2025 | finance.yahoo.com

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

April 14, 2025 | globenewswire.com

NKGen Biotech presents data from Phase 1/2a trial of troculeucel

April 9, 2025 | markets.businessinsider.com

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

April 7, 2025 | globenewswire.com

NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference

March 27, 2025 | nasdaq.com

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

March 25, 2025 | markets.businessinsider.com

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

March 25, 2025 | globenewswire.com

NKGen Biotech Treats First Stroke Patient With Troculeucel Cell Therapy

March 5, 2025 | precisionmedicineonline.comP

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

March 4, 2025 | markets.businessinsider.com

NKGen Biotech, Inc. Transitions to OTC Markets Following Nasdaq Delisting, Retaining Compliance with SEC Reporting Requirements

March 4, 2025 | quiverquant.comQ

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

March 4, 2025 | globenewswire.com

NKGen Biotech announces administration of first dose of troculeucel

March 3, 2025 | markets.businessinsider.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

March 3, 2025 | globenewswire.com

NKGen administers first troculeucel dose under compassionate use program

February 21, 2025 | markets.businessinsider.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

February 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, ALVR, NKGN, and CLDI Company Descriptions

AlloVir NASDAQ:ALVR

$2.49 +0.13 (+5.51%)

As of 06/24/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Calidi Biotherapeutics NYSE:CLDI

$0.23 -0.03 (-11.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.23 +0.00 (+1.48%)

As of 08:00 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

NKGen Biotech NYSE:NKGN

$0.22 -0.02 (-9.17%)

As of 03:25 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time